Introduction

Joint wear is common in weight-bearing joints such as the knees and hips, often causing pain and limiting movement, and cartilage does not heal well on its own. This article explains ChondroFiller, a non-surgical, injectable collagen gel used to support the joint, with realistic expectations throughout.

What Is ChondroFiller?

ChondroFiller is a CE-marked Class III medical device — a collagen-based gel that is injected directly into the joint. It is manufactured by Meidrix Biomedicals in Germany and imported into the UK under prescription. ChondroFiller is cell-free, so unlike treatments that harvest and reintroduce living cells, no cells are taken from the patient. Once in the joint, it may settle over worn surfaces, adding a protective, cushioning layer that helps reduce grinding.

How It Works

The gel is injected into the joint, typically guided by ultrasound imaging to ensure accurate placement. It adds a protective collagen layer that may cushion the joint. The scaffold recruits the patient's own progenitor cells from the surrounding tissue, providing a biological environment that supports cartilage repair. Scientific studies note that its gel can absorb load and adapt to the forces inside a joint (Weizel et al., 2020). Because it is collagen-based, it has biological potential, but it is best understood as a supportive, joint-preserving injection — not a guaranteed repair, cure, or reversal of arthritis.

The Advantages of an Injectable, Cell-Free Approach

Compared with open surgery or cell-based treatments, ChondroFiller does not require taking cells from the patient or a donor, and it is injected rather than implanted through an operation. This makes it minimally invasive, usually with a quicker recovery, fewer risks, and a simpler overall process. As an outpatient procedure, most patients can return to normal activities without the structured rehabilitation period that surgical cartilage repair requires.

How ChondroFiller Differs from Liquid Cartilage

It is worth clarifying a distinction that often causes confusion. ChondroFiller is the collagen scaffold — the material itself. The ChondroFiller injection is a non-surgical, ultrasound-guided outpatient procedure suited to accessible lesions and cases where surgery is not warranted.

Liquid Cartilage is a separate and different thing: it is the Lee Liquid Cartilage Protocol, Professor Paul Lee's keyhole surgical technique. That procedure delivers the ChondroFiller scaffold arthroscopically, combined with biological adjuncts such as platelet-rich fibrin or platelet-rich plasma and, where indicated, the patient's own mesenchymal stem cells from bone-marrow concentrate or micro-fragmented fat. Liquid Cartilage is genuine surgery — carried out in theatre under anaesthetic with a structured recovery programme — and is intended for larger or more complex defects in load-bearing joints. The CE marking and device evidence belong to ChondroFiller (the material); Liquid Cartilage is the surgical protocol that uses it.

Conclusion

ChondroFiller is a non-surgical, injectable collagen gel that may help support a worn joint and ease symptoms for some people, with a minimally invasive approach. Results vary from person to person. At the London Cartilage Clinic, specialist assessment can help establish whether the ChondroFiller injection or the Liquid Cartilage surgical protocol is the more appropriate pathway for a given patient's circumstances. For personalised advice, please consult a qualified healthcare professional.

References

• Weizel, A., Distler, T., Schneidereit, D., & Friedrich, O. (2020). Complex mechanical behavior of human articular cartilage and hydrogels for cartilage repair. Acta Biomaterialia.
• Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.